#Canada #Victoria #Eosinophilic Esophagitis #Eupraxia Pharmaceuticals #EP-104GI

Eupraxia Pharmaceuticals Announces Positive Trial Results for EP-104GI

Eupraxia Pharmaceuticals Inc. has recently announced noteworthy results from its ongoing RESOLVE Phase 1b/2a clinical trial, which investigates the efficacy of EP-104GI for treating eosinophilic esophagitis (EoE). As an inflammatory disease where eosinophils accumulate in the esophagus, EoE leads to significant challenges in swallowing and managing symptoms for patients. The results from this trial could potentially change the treatment landscape for individuals suffering from EoE.

Key Findings from the Latest Cohort

In the RESOLVE trial, Cohort 6 demonstrated remarkable improvements in histological scores and symptom severity as the dosage and targeted coverage area increased. Specifically, this cohort—where patients received 16 injections of 4 mg EP-104GI, covering 80% of the esophagus—showed a peak reduction in symptom severity of up to 71%, averaging a 46% reduction in symptom scores at the 12-week mark. This could encourage future investigations into dose and coverage adjustments for effective relief.

Symptom and Tissue Health Improvements

The tissue analysis from Cohort 6 indicated an unprecedented 94% reduction in Peak Eosinophil Count (PEC), which denotes the number of eosinophils found in esophageal biopsies. Additionally, the histological measures showed significant improvements, with reductions of 89% and 88% in stage and grade scores, respectively. These results suggest that EP-104GI is yielding strong efficacy, supporting further exploration at higher doses and expanded coverage to maximize treatment effectiveness.

Dr. James Helliwell, CEO of Eupraxia, emphasized that no serious adverse events have arisen, maintaining the safety profile of EP-104GI—a crucial element in the design of clinical therapies for EoE, especially against the backdrop of steroid treatments that often lead to side effects.

Safety and Efficacy in Focus

The RESOLVE trial, which is multi-center and open-label, is systematically assessing the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI, providing a clear dose-response relationship that enhances patient care. The data continue to affirm that this localized approach may serve as new standard care for EoE, with Eupraxia aiming to maximize the drug's potential by optimizing esophageal coverage.

Upcoming Developments

With Cohort 7 fully enrolled and data from this group expected in the second quarter of 2025, Eupraxia plans to maintain proactive communication through webinars and updates, keeping stakeholders informed on progress and findings. The upcoming webinar scheduled for February 26 will offer insights into the RESOLVE trial's data, shedding light on the transformative potential of EP-104GI.

Understanding Eosinophilic Esophagitis

Currently, EoE affects more than 450,000 people in the U.S. alone, often leading to compounded issues such as mental health challenges due to ongoing health struggles. Eupraxia's commitment to developing tailored treatment solutions is framed within a broader context of a healthcare system that grapples with growing demands for effective therapies.

Conclusion

The results from the RESOLVE trial have positioned EP-104GI as a promising contender in the management of eosinophilic esophagitis. With increased evidence supporting its efficacy and safety, Eupraxia Pharmaceuticals continues to advance its mission of addressing significant unmet medical needs in chronic inflammatory conditions. As further data emerges, both patients and practitioners alike will be looking forward to improvements in the therapeutic landscape surrounding EoE.

For more details about this breakthrough and to register for the upcoming webinar, visit Eupraxia's website at Eupraxia Pharmaceuticals.